Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dollar Tree (DLTR) upgraded to Outperform from Market Perform at Bernstein with analyst Brandon Fletcher saying while he still wants to see activism, he thinks management has done "enough" at the current valuation to make the grade. 2. Lattice Semiconductor (LSCC) upgraded to Outperform from Neutral at Baird with analyst Tristan Gerra saying Lattice has a highly defensible business model, in need of improved execution. 3. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the upgrade is based on "broad-based market share momentum, an improving gross margin outlook, and greater earnings achievability are not adequately reflected in relative valuation vs. peers." 4. Regeneron (REGN) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying he sees 25% upside after boosting his price target for the shares to $472 from $415. 5. Bausch Health (BHC) upgraded to Buy from Neutral at H.C. Wainwright analyst Raghuram Selvaraju saying now is an "appropriate time to become more bullish on the story." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.